Article content material
MONTREAL, Oct. 31, 2024 (GLOBE NEWSWIRE) — Knight Therapeutics Inc. (TSX: GUD) (“Knight”), a number one pan-American (ex-USA) specialty pharmaceutical firm, will launch its third quarter 2024 monetary outcomes on Thursday, November 7, 2024, previous to market opening. Following the discharge, Knight will maintain a convention name and audio webcast. Knight cordially invitations all events to take part on this name.
Date: Thursday, November 7, 2024
Time: 8:30 a.m. ET
Phone: Toll Free: 1-800-836-8184 or Worldwide 1-289-819-1350
Webcast: www.knighttx.com or Webcast
This can be a listen-only audio webcast. Media Participant is required to take heed to the published.
Replay: An archived replay can be out there for 30 days at www.knighttx.com.
Article content material
About Knight Therapeutics Inc.
Knight Therapeutics Inc., headquartered in Montreal, Canada, is a specialty pharmaceutical firm targeted on buying or in-licensing and commercializing pharmaceutical merchandise for Canada and Latin America. Knight’s Latin American subsidiaries function beneath United Medical, Biotoscana Farma and Laboratorio LKM. Knight Therapeutics Inc.’s shares commerce on TSX beneath the image GUD. For extra details about Knight Therapeutics Inc., please go to the corporate’s site at www.knighttx.com or www.sedarplus.ca.
Ahead-Trying Assertion
This doc accommodates forward-looking statements for Knight Therapeutics Inc. and its subsidiaries. These forward-looking statements, by their nature, essentially contain dangers and uncertainties that might trigger precise outcomes to vary materially from these contemplated by the forward-looking statements. Knight Therapeutics Inc. considers the assumptions on which these forward-looking statements are primarily based to be affordable on the time they had been ready however cautions the reader that these assumptions concerning future occasions, lots of that are past the management of Knight Therapeutics Inc. and its subsidiaries, might finally show to be incorrect. Components and dangers which might trigger precise outcomes to vary materially from present expectations are mentioned in Knight Therapeutics Inc.’s Annual Report and in Knight Therapeutics Inc.’s Annual Data Kind for the yr ended December 31, 2023, as filed on www.sedarplus.ca. Knight Therapeutics Inc. disclaims any intention or obligation to replace or revise any forward-looking statements, whether or not because of new info or future occasions, besides as required by regulation.
Share this text in your social community
